Moat Biotechnology (MoatBio), a spin-out from Tetherex Pharmaceuticals, announced that it has closed a funding round of more than $6.5 million following an initial funding led by Cortado Ventures in September 2022. The company says that it intends to use the proceeds for continued development of an inhaled/intranasal COVID-19 vaccine based on the SC-AdVax single-cycle … [Read more...] about Moat Biotechnology raises $6.5 million for development of intranasal/inhaled COVID-19 vaccine
News
Gilbert Technologies raises €7 million for development of its soft mist inhaler device
Dutch device company Gilbert Technologies has announced the closing of a €7 million funding round led by DeepTechXL. The company said that Brabant Startup Funds also converted its earlier loan to Gilbert Technologies, making Brabant a shareholder, along with current shareholders NanoCorp and Delft Enterprises. According to Gilbert, the proceeds of the funding will … [Read more...] about Gilbert Technologies raises €7 million for development of its soft mist inhaler device
Vistagen announces results from Phase 2a trial of PH80 epoxyestrenolone nasal spray for the treatment of hot flashes
Vistagen announced that a Phase 2a trial of the company's PH80 intranasal epoxyestrenolone in menopausal women experiencing hot flashes demonstrated statistically significant reduction in the frequency and severity of the hot flashes. The company acquired PH80 when it acquired Pherin Pharmaceuticals earlier this year and the Phase 2a trial was conducted by Pherin at … [Read more...] about Vistagen announces results from Phase 2a trial of PH80 epoxyestrenolone nasal spray for the treatment of hot flashes
InhaleRx initiates Phase 1 trial of IRX211 dronabinol MDI
Australian inhaled cannabis developer InhaleRx (formerly Lifespot Health) announced the initiation of a Phase 1 SAD study of the company's IRX211 inhaled dronabinol, a synthetic THC. According to the company, IRX211 was formulated by "a specialized inhalation expert group based in the UK," and the clinical trial batch was manufactured by Ab Initio Pharma. InhaleRx is … [Read more...] about InhaleRx initiates Phase 1 trial of IRX211 dronabinol MDI
Alpha Cognition gets $750,000 grant from US military for development of ALPHA-1062 intranasal galantamine for the treatment of brain injury
Alpha Cognition announced that the Army Medical Research and Material Command has awarded the company a $750,000 grant to support a pre-clinical study of the possible use of ALPHA-1062 Intranasal galantamine for the treatment of blast-induced mild traumatic brain injury (mTBI). According to Alpha Cognition, the study will be conducted in partnership with the Seattle … [Read more...] about Alpha Cognition gets $750,000 grant from US military for development of ALPHA-1062 intranasal galantamine for the treatment of brain injury
CQDM provides funding for Oragenics intranasal COVID-19 vaccine
According to Oragenics, Canadian biopharmaceutical research consortium CQDM has awarded a grant for development of variant-agnostic protein antigens for use in an intranasal COVID-19 vaccine that "aims to build upon Oragenics’ current lead intranasal vaccine candidate NT-CoV2-1." According to the CQDM web site, the total value of the project is $1.64 million, with … [Read more...] about CQDM provides funding for Oragenics intranasal COVID-19 vaccine
Aerami Therapeutics announces appointment of interim CEO and additional management positions
Aerami Therapeutics has announced the promotion of Joshua Ziel from Chief of Staff and VP, Program Development to Chief Operating Officer and interim CEO. Executive Chairwoman Anne Whitaker had been leading Aerami since the sudden death of CEO Lisa Yañez in May 2023. The company also announced the appointments of Gary Burgess as Chief Medical Officer and Sarah … [Read more...] about Aerami Therapeutics announces appointment of interim CEO and additional management positions
Aerosol School goes virtual for 2023
After pausing for several years due to the COVID-19 pandemic, the 2023 edition of Aerosol School will take place virtually. Students will have access to more than 200 hours of lectures from well-known experts on topics ranging from the basics of aerosol delivery devices to hot topics such as the delivery of macrophages and monoclonal antibodies via inhalation. … [Read more...] about Aerosol School goes virtual for 2023
Pneumagen raises £8 million for Phase 2 trial of Neumafil nasal spray in COPD patients
Pneumagen said that it has closed an £8 million funding round, with proceeds going to support Phase 2 development of the company's Neumifil multivalent carbohydrate binding module (mCBM) nasal spray, including a Phase 2b trial in COPD patients experiencing exacerbations caused by viral infection that is expected to be initiated in 2024. The company announced in … [Read more...] about Pneumagen raises £8 million for Phase 2 trial of Neumafil nasal spray in COPD patients
Nephron Pharmaceuticals announces availability of albuterol sulfate inhalation solution in 25mg/5ml vials
Nephron Pharmaceuticals announced that the company is now offering 0.5% albuterol sulfate inhalation solution in 5 ml vials for direct shipping to US medical facilities in response to a nationwide shortage. Ritedose Pharmaceuticals recently announced that if would begin manufacturing 0.5% albuterol in response to the shortage. Nephron notes that has been manufacturing … [Read more...] about Nephron Pharmaceuticals announces availability of albuterol sulfate inhalation solution in 25mg/5ml vials